Epirubicin (E)

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, Second Affiliated Hospital, School of Medicine, Zhejiang University, Eye & ENT Hospital of Fudan University

Conditions

Adenoid Cystic CarcinomaBreast CancerER+/HER2- Breast CancerEpirubicinSinonasal Carcinoma

Phase 2

Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)

RecruitingNCT06964906

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityER+/HER2- Breast Cancer

Start: 2025-03-04End: 2030-12-31Target: 140Updated: 2025-05-11

Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study

RecruitingNCT07320508

Eye & ENT Hospital of Fudan UniversityAdenoid Cystic Carcinoma, Epirubicin, Sinonasal Carcinoma

Start: 2026-01-20End: 2029-12-12Target: 100Updated: 2026-01-21

Phase 3

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Active, not recruitingNCT03725059

Merck Sharp & Dohme LLCBreast Cancer

Start: 2018-12-27End: 2031-01-24Target: 1240Updated: 2025-07-11

Related Papers

Abstract P1-11-20: Chemotherapy use in patients with early-stage high-risk ER+/HER2- breast cancer in the United States (US) community setting: A retrospective observational cohort study

Clinical Cancer Research2025-06-13

Pembrolizumab and chemotherapy in high-risk, early-stage, ER<sup>+</sup>/HER2<sup>-</sup> breast cancer: a randomized phase 3 trial.

2025-01-2158 citations

Checkpoint inhibition for early-stage hormone receptor-positive breast cancer.

2024-06-245 citations

Abstract GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756

Cancer Research2024-05-0216 citations

Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer.

2022-12-2715 citations

KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.

Journal of Clinical Oncology2019-05-2025 citations